Efficacy and Tolerability of Toremifene or Tamoxifen Therapy in Premenopausal Estrogen and Progesterone Receptor Positive Breast Cancer Patients
Conditions
Breast Cancer Patients in Premenopausal - Estrogen and/or Progesterone Receptor Positive
Study Type
Interventional
Study Phase
Phase 2/Phase 3
Study Design
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Intervention
Name: toremifene or tamoxifen
Type: Drug
Overall Status
Recruiting
Summary
In premenopausal women, endocrine adjuvant therapy for breast cancer primarily consists of tamoxifen alone or with ovarian suppressive strategies. Toremifene is a chlorinated derivative of tamoxifen, but with a superior risk-benefit profile. In this trial, we sought to compare the efficacy and tolerability of toremifene and tamoxifen therapy in premenopausal patients with operable,estrogen and/or progesterone receptor positive breast cancer patients.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: 60 Years
Minimum Age: 18 Years
Gender: Female
Criteria: Inclusion Criteria:

- Clinical diagnosis of Breast cancer

- Received standard treatment (chemotherapy, operation, or radiotherapy)

- premenopausal

- estrogen and/or progesterone receptor positive

Exclusion Criteria:

- Metastatic tumors

- During pregnancy or lactation
Location
Breast cancer center of Sun Yat-sen Memorial Hospital
Guangzhou, Guangdong, China
Status: Recruiting
Contact: Yaping yang, master - 0086-020-34071145 - yypapple1225@163.com
Start Date
April 2014
Completion Date
May 2020
Sponsors
Fengxi Su
Source
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page